skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Acrolein consumption induces systemic dyslipidemia and lipoprotein modification

Journal Article · · Toxicology and Applied Pharmacology
;  [1]; ; ;  [2];  [3]; ; ;  [1];  [1]
  1. Diabetes and Obesity Center, University of Louisville, Louisville, KY 40202 (United States)
  2. Centre for Functional Genomics and Bio-Chips (CFGBC), Institute of Biochemistry, Faculty of Medicine, University of Ljubljana, Zaloska 4, SI-1000 Ljubljana (Slovenia)
  3. Department of Biochemistry and Molecular Biology, University of Louisville, Louisville, KY 40202 (United States)

Aldehydes such as acrolein are ubiquitous pollutants present in automobile exhaust, cigarette, wood, and coal smoke. Such aldehydes are also constituents of several food substances and are present in drinking water, irrigation canals, and effluents from manufacturing plants. Oral intake represents the most significant source of exposure to acrolein and related aldehydes. To study the effects of short-term oral exposure to acrolein on lipoprotein levels and metabolism, adult mice were gavage-fed 0.1 to 5 mg acrolein/kg bwt and changes in plasma lipoproteins were assessed. Changes in hepatic gene expression related to lipid metabolism and cytokines were examined by qRT-PCR analysis. Acrolein feeding did not affect body weight, blood urea nitrogen, plasma creatinine, electrolytes, cytokines or liver enzymes, but increased plasma cholesterol and triglycerides. Similar results were obtained with apoE-null mice. Plasma lipoproteins from acrolein-fed mice showed altered electrophoretic mobility on agarose gels. Chromatographic analysis revealed elevated VLDL cholesterol, phospholipids, and triglycerides levels with little change in LDL or HDL. NMR analysis indicated shifts from small to large VLDL and from large to medium-small LDL with no change in the size of HDL particles. Increased plasma VLDL was associated with a significant decrease in post-heparin plasma hepatic lipase activity and a decrease in hepatic expression of hepatic lipase. These observations suggest that oral exposure to acrolein could induce or exacerbate systemic dyslipidemia and thereby contribute to cardiovascular disease risk.

OSTI ID:
21344859
Journal Information:
Toxicology and Applied Pharmacology, Vol. 243, Issue 1; Other Information: DOI: 10.1016/j.taap.2009.12.010; PII: S0041-008X(09)00517-1; Copyright (c) 2009 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.; ISSN 0041-008X
Country of Publication:
United States
Language:
English

Similar Records

Endothelial lipase is a major determinant of HDL level
Journal Article · Thu Jan 30 00:00:00 EST 2003 · Journal of Clinical Investigation · OSTI ID:21344859

Apolipoprotein A-V Deficiency Results in MarkedHypertriglyceridemia Attributable to Decreased Lipolysis ofTriglyceride-Rich Lipoproteins and Removal of Their Remnants
Journal Article · Thu Sep 01 00:00:00 EDT 2005 · Arteriosclerosis, Thrombosis and VascularBiology · OSTI ID:21344859

Apolipoprotein AV Accelerates Plasma Hydrolysis OfTriglyceride-Rich Lipoproteins By Interaction With Proteoglycan BoundLipoprotein Lipase
Journal Article · Tue Feb 22 00:00:00 EST 2005 · The Journal of Biological Chemistry · OSTI ID:21344859